Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, April 28, 2017 8:36:19 AM
NESS ZIONA, Israel, April 28, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV; TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its fourth quarter and full year financial results for the year ended December 31, 2016, and provided a business update.
The Company also filed its annual report for the year ended December 31, 2016, on Form 20F with the U.S. Securities and Exchange Commission. This can be downloaded from BiondVax's website.
Fourth Quarter 2016 Financial Summary
Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.845 as at December 31, 2016.
Fourth quarter operating expenses, net, were NIS 3.12 million ($811,000) compared with NIS 4.06 million in the fourth quarter of last year;
Fourth quarter R&D expenses, net, amounted to NIS 1.83 million ($476,000) compared with NIS 2.87 million in the fourth quarter of last year;
Full Year 2016 Financial Summary
Total operating expenses, net, were NIS 11.90 million ($3.10 million) compared with NIS 11.30 million in 2015;
R&D expenses, net, amounted to NIS 7.79 million ($2.03 million) compared with NIS 7.91 million in 2015;
As of December 31, 2016, BiondVax had cash and cash equivalents, short-term investments and marketable securities of NIS 27.4 million ($7.1 million) as compared to NIS 37.5 million as of December 31, 2015. This decrease was attributable to utilization of available cash resources to fund operations.
Recent Corporate Update
The Company announced positive preliminary safety results from the Phase 2b clinical trial of M-001, conducted in collaboration with the European UNISEC consortium[1]. Immunogenicity results, currently being processed by other UNISEC consortium entities, are expected by the end of Q2 2017.
In January 2017, Angels High Tech Investments Ltd. invested NIS 10.9 million, approximately $2.8 million, in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange (equivalent to 844,000 NASDAQ listed ADS) at the December 29, 2016, Tel Aviv closing market price. Following the transaction, Angels Investments held 19.99% of all issued and outstanding share capital of the Company.
The peer-reviewed journal Vaccine published an article titled, "Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain." The article reports that blood plasma samples from people who received M-001 in 2011 (as part of BiondVax's BVX-005 clinical trial in the elderly) showed a five-fold significant increase of protective antibodies against a new epidemic 2014/15 flu strain (A/Swiss) – a strain which did not exist when M-001 was administered to the BVX-005 participants.
An article by BiondVax-affiliated authors titled, "Strategy for approving a universal flu vaccine" was published in the peer-reviewed journal Future Virology.
The Company received approval for a grant representing 20% of a NIS 20 million budget from Israel's Ministry of Economy and Industry to build a facility for commercial scale production of M-001, its universal flu vaccine candidate.
Dr. Ron Babecoff, BiondVax's President and CEO, commented, "I am pleased we are progressing and keeping expenses at the planned level. Recent reports in CNN[2],[3] and The Washington Times[4] indicate flu pandemic threats like H7N9 are an increasingly urgent concern. Current solutions are insufficient. These concerns strengthen our unwavering commitment to bring our universal flu vaccine candidate to the market to improve pandemic preparedness."
[1] UNISEC research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012.
[2] The big one is coming, and it's going to be a flu pandemic. http://edition.cnn.com/2017/04/07/health/flu-pandemic-sanjay-gupta/index.html.
[3] Seven reasons we're at more risk than ever of a global pandemic. http://edition.cnn.com/2017/04/03/health/pandemic-risk-virus-bacteria/.
[4] Congress, WHO sound the alarm over pandemic avian flu in China. http://www.washingtontimes.com/news/2017/apr/21/congress-who-sound-alarm-over-pandemic-bird-flu-or/.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.
Recent BVXV News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/07/2023 09:27:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 04:01:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 03:44:03 PM
- BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics • GlobeNewswire Inc. • 09/06/2023 10:00:00 AM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 08/28/2023 08:01:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/28/2023 04:15:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/24/2023 08:05:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2023 10:10:14 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/18/2023 08:16:19 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/18/2023 02:07:35 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/14/2023 10:08:59 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/11/2023 01:44:48 PM
- BiondVax Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/11/2023 01:00:00 PM
- Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules • GlobeNewswire Inc. • 08/01/2023 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2023 08:00:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2023 07:10:31 PM
- IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. • GlobeNewswire Inc. • 07/11/2023 12:17:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/05/2023 01:17:40 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM